Allergy Diagnostics and Therapeutics Market Size and Share - Growth Analysis Report and Forecast Trends (2026-2035)

Allergy Diagnostics and Therapeutics Market Overview

Allergy diagnostics and therapeutics include in-vivo skin tests, in-vitro IgE assays, allergen extracts, antihistamines, corticosteroids, biologics, autoinjectable epinephrine, and immunotherapy products used to identify and manage allergic conditions. The market was valued at USD 40.45 Billion in 2025. The market is experiencing steady growth driven by rising allergy prevalence, technological advancements, and increasing adoption of genomics-driven therapy, multi-omics integration, and companion diagnostics. Expanding awareness, improved healthcare infrastructure, and the shift toward personalized dosing and precision medicine are further strengthening market expansion globally.

Allergy Diagnostics and Therapeutics Market Growth Drivers

Rising Global Prevalence of Allergic Diseases is Set to Boost Allergy Diagnostics and Therapeutics Market Expansion

The growing prevalence of food, respiratory, and skin allergies is the leading driver of demand for allergy diagnostics and therapeutics. According to Lauren Bottoms-McClain et al.2026, in 2024, 31.7% of adults in the United States had diagnosed seasonal allergies, eczema, or food allergies, with 25.2% affected by seasonal allergies alone. The study also highlighted demographic variations, including higher eczema prevalence among women and differences across geographic regions. This rising disease burden continues to strengthen demand for advanced allergy diagnostics and treatment solutions, thereby driving sustained market growth..

Allergy Diagnostics and Therapeutics Market Trends

A notable trend in the market includes the adoption of biologics and the expansion of allergen immunotherapy.

Increasing Adoption of Biologics and Allergen Immunotherapy is Likely to Boost Allergy Diagnostics and Therapeutics Market Growth

Manufacturers and regulators are accelerating the shift toward biologics and allergen immunotherapy. In February 2024, the U.S. FDA approved Xolair (omalizumab) for IgE-mediated food allergy in patients aged one year and older, becoming the first medicine indicated to reduce reactions across multiple foods. In June 2025, ALK received European approval for the Itulazax tree pollen sublingual tablet in children and adolescents. Enhances treatment effectiveness, expands patient eligibility, and drives sustained demand for advanced therapies.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Allergy Diagnostics and Therapeutics Market Segmentation

Allergy Diagnostics and Therapeutics Market Share

Food Allergen Segment to Lead the Market by Allergen Type

The market is segmented by allergen type into food, drug, and others, each addressing distinct diagnostic and treatment pathways. The market is segmented by allergen type into food, drug, and others, each representing distinct sources of allergic reactions and corresponding diagnostic and therapeutic approaches. Among these, the food allergen segment is expected to lead due to the increasing global prevalence of food allergies and heightened awareness regarding early diagnosis and management. The growing adoption of advanced diagnostic techniques, along with a strong focus on targeted treatment approaches, continues to drive this segment. As healthcare systems emphasize accurate identification and effective management, the food allergen segment is poised to maintain its dominant position over the forecast period.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Purchase the Regional Overview for USD 1099

If you choose to purchase the full report at a later stage, the amount already paid will be adjusted, and you will only need to pay the remaining balance.

Allergy Diagnostics and Therapeutics Market Analysis by Region

North America is expected to dominate the global allergy diagnostics and therapeutics market, supported by high allergic disease prevalence, advanced laboratory infrastructure, and a strong concentration of leading manufacturers. According to the Centers for Disease Control and Prevention, in 2024, 31.7% of adults and 29.5% of children reported at least one allergic condition in the United States. Asia Pacific is anticipated to grow at the fastest pace, supported by rising urbanisation, expanding clinical laboratories, and growing awareness across China, Japan, and India.

Leading Players in the Allergy Diagnostics and Therapeutics Market

Key Questions Answered in the Allergy Diagnostics and Therapeutics Market Report

• What was the allergy diagnostics and therapeutics market value in 2025?
• What is the allergy diagnostics and therapeutics market forecast outlook for 2026-2035?
• What major factors aid the demand for the allergy diagnostics and therapeutics market?
• How has the market performed so far, and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints?
• What are the major allergy diagnostics and therapeutics market trends?
• Which offering is expected to dominate the market segment?
• Which allergen type is projected to lead the segment?
• Which end user is anticipated to lead the market?
• Who are the key players in the allergy diagnostics and therapeutics market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers, and acquisitions among the key market players shaping the market dynamics?